- Home
- WLYB vs PRCT Comparison
WLYB vs PRCT Comparison
Compare WLYB & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- PRCT
- Stock Information
- Founded
- WLYB 1807
- PRCT 2009
- Country
- WLYB United States
- PRCT United States
- Employees
- WLYB N/A
- PRCT N/A
- Industry
- WLYB Books
- PRCT Medical Specialities
- Sector
- WLYB Consumer Discretionary
- PRCT Health Care
- Exchange
- WLYB Nasdaq
- PRCT Nasdaq
- Market Cap
- WLYB 2.0B
- PRCT 2.2B
- IPO Year
- WLYB N/A
- PRCT 2021
- Fundamental
- Price
- WLYB $39.94
- PRCT $40.12
- Analyst Decision
- WLYB
- PRCT Buy
- Analyst Count
- WLYB 0
- PRCT 8
- Target Price
- WLYB N/A
- PRCT $75.57
- AVG Volume (30 Days)
- WLYB 116.0
- PRCT 1.6M
- Earning Date
- WLYB 09-04-2025
- PRCT 08-06-2025
- Dividend Yield
- WLYB 3.54%
- PRCT N/A
- EPS Growth
- WLYB N/A
- PRCT N/A
- EPS
- WLYB 1.53
- PRCT N/A
- Revenue
- WLYB $1,677,609,000.00
- PRCT $274,950,000.00
- Revenue This Year
- WLYB $1.45
- PRCT $47.51
- Revenue Next Year
- WLYB $2.70
- PRCT $31.69
- P/E Ratio
- WLYB $25.55
- PRCT N/A
- Revenue Growth
- WLYB N/A
- PRCT 55.71
- 52 Week Low
- WLYB $37.27
- PRCT $37.12
- 52 Week High
- WLYB $52.90
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- WLYB 39.96
- PRCT 26.56
- Support Level
- WLYB $41.30
- PRCT $37.32
- Resistance Level
- WLYB $42.70
- PRCT $40.86
- Average True Range (ATR)
- WLYB 0.00
- PRCT 2.69
- MACD
- WLYB 0.09
- PRCT -1.02
- Stochastic Oscillator
- WLYB 100.00
- PRCT 15.19
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.